Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    XTL Biopharmaceuticals Lt...

    NASDAQ: XTLB · Real-Time Price · USD
    1.22
    0.10 (8.93%)
    At close: Jun 16, 2025, 3:56 PM
    1.17
    -4.10%
    After-hours: Jun 16, 2025, 06:06 PM EDT

    XTL Biopharmaceuticals Statistics

    Share Statistics

    XTL Biopharmaceuticals has 8.81M shares outstanding. The number of shares has increased by 191.25% in one year.

    Shares Outstanding

    n/a
    		 8.81M

    Shares Change (YoY)

    n/a
    		 191.25%

    Shares Change (QoQ)

    n/a
    		 15.9%

    Owned by Institutions (%)

    n/a
    		 0.04%

    Shares Floating

    n/a
    		 8.6M

    Failed to Deliver (FTD) Shares

    n/a
    		 200

    FTD / Avg. Volume

    n/a
    		 2.33%

    Short Selling Information

    The latest short interest is 36.62K, so 0.42% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 36.62K

    Short % of Shares Out

    n/a
    		 0.42%

    Short % of Float

    n/a
    		 0.55%

    Short Ratio (days to cover)

    n/a
    		 7.51

    Valuation Ratios

    The PE ratio is -13.3 and the forward PE ratio is null. XTL Biopharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 -13.3

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 30.29

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 2.51

    P/FCF Ratio

    n/a
    		 -8.17

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for XTL Biopharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.61, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 0.61

    Quick Ratio

    n/a
    		 0.61

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.08

    Interest Coverage

    n/a
    		 -77.57

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $45,100

    Profits Per Employee

    n/a
    		 $-102,700

    Employee Count

    n/a
    		 10

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -130K

    Effective Tax Rate

    n/a
    		 11.24%

    Stock Price Statistics

    The stock price has increased by -50% in the last 52 weeks. The beta is 0.99, so XTL Biopharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.99

    52-Week Price Change

    n/a
    		 -50%

    50-Day Moving Average

    n/a
    		 1.22

    200-Day Moving Average

    n/a
    		 1.69

    Relative Strength Index (RSI)

    n/a
    		 52.06

    Average Volume (20 Days)

    n/a
    		 8,601

    Income Statement

    In the last 12 months, XTL Biopharmaceuticals had revenue of 451K and earned -1.03M in profits. Earnings per share was -0.15.

    Revenue

    n/a
    		 451K

    Gross Profit

    n/a
    		 3K

    Operating Income

    n/a
    		 -2.17M

    Net Income

    n/a
    		 -1.03M

    EBITDA

    n/a
    		 -930K

    EBIT

    n/a
    		 -1.13M

    Earnings Per Share (EPS)

    n/a
    		 -0.15
    Full Income Statement

    Balance Sheet

    The company has 371K in cash and 138K in debt, giving a net cash position of 233K.

    Cash & Cash Equivalents

    n/a
    		 371K

    Total Debt

    n/a
    		 138K

    Net Cash

    n/a
    		 233K

    Retained Earnings

    n/a
    		 -159.01M

    Total Assets

    n/a
    		 8.55M

    Working Capital

    n/a
    		 -867K
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -1.62M and capital expenditures -54K, giving a free cash flow of -1.67M.

    Operating Cash Flow

    n/a
    		 -1.62M

    Capital Expenditures

    n/a
    		 -54K

    Free Cash Flow

    n/a
    		 -1.67M

    FCF Per Share

    n/a
    		 0
    Full Cash Flow Statement

    Margins

    Gross margin is 0.67%, with operating and profit margins of -481.6% and -227.72%.

    Gross Margin

    n/a
    		 0.67%

    Operating Margin

    n/a
    		 -481.6%

    Pretax Margin

    n/a
    		 -256.54%

    Profit Margin

    n/a
    		 -227.72%

    EBITDA Margin

    n/a
    		 -206.21%

    EBIT Margin

    n/a
    		 -481.6%

    FCF Margin

    n/a
    		 -370.73%

    Dividends & Yields

    XTLB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for XTLB.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 10, 2017. It was a backward split with a ratio of 1:5.

    Last Split Date

    n/a
    		 Feb 10, 2017

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:5

    Scores

    Altman Z-Score

    n/a
    		 -24.85

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist